Literature DB >> 31895069

Does a Competing Risk Analysis Show Differences in the Cumulative Incidence of Revision Surgery Between Patients with Oncologic and Non-oncologic Conditions After Distal Femur Replacement?

Kevin Staats1, Klemens Vertesich1, Irene K Sigmund1, Branden Sosa2, Alexandra Kaider3, Phillip T Funovics1, Reinhard Windhager1.   

Abstract

BACKGROUND: Distal femur replacement is frequently used for limb salvage after bone tumor resections. It is also used in patients with severe bone loss because of traumatic conditions or revision TKA. Some studies on distal femur replacement reported on revision-free survival without distinguishing between patients with oncologic diagnoses and those without, although these patients might be incomparable because of their differences in important patient- and disease-specific characteristics. This may lead to an inaccurate and undifferentiated interpretation of the results of survival analyses. QUESTIONS/PURPOSES: (1) What is the overall cumulative incidence of revision surgery after cemented and cementless distal femoral replacement, as determined with a competing risk analysis? (2) Does the cumulative incidence of revision surgery change over time? (3) Are there differences in the cumulative incidence of revision surgery between patients with oncologic conditions and those without who are treated with cemented or cementless distal femoral replacement?
METHODS: A total of 403 patients were possible candidates for distal femoral replacement. Of these, 56 patients elected to undergo different procedures, 83 were excluded because an expendable growing prosthesis was implanted, and 28 were lost to follow-up. Therefore, 229 patients who underwent distal femoral replacement for oncologic or non-oncologic reasons between 1983 and 2016 were retrospectively included in this study. The type of fixation method (cemented or cementless) was obtained from the patients' medical records, operation reports, and radiographic analyses from plain radiographs. All radiographs were standardized and obtained at standard time intervals in our institution. No algorithm regarding the fixation approach was followed. According to our data, patients receiving cementless fixation were younger and therefore likely to be more active than those receiving cemented fixation. The median follow-up duration of the overall cohort was 85 months (range 0.1-391 months). Patients who died or had revision surgery before the 2-year minimum follow-up interval were adequately considered using competing risk calculation. The reasons for revision surgery were classified using the classification system proposed by the International Society for Limb Salvage. A competing risk analysis was performed to estimate the cumulative incidence function of revision, accounting for death as a competing event. To evaluate the influence of potential prognostic factors, including diagnosis (oncologic versus non-oncologic), fixation (cemented versus cementless), year of distal femoral replacement, age, and sex on the occurrence of revision surgery, univariate and multivariable Fine and Gray models were applied.
RESULTS: The competing risks analysis revealed cumulative incidences of revision surgery for any cause (Types 1 to 5) of 26% (95% CI, 20.3%-31.9%) at 12 months, 37.9% (95% CI, 31.3%-44.4%) at 24 months, 52.6% (95% CI, 45.1%-59.5%) at 5 years, and 58.2% (95% CI, 50.1%-65.4%) at 10 years for all patients. Rotating hinge-type prostheses showed a lower cumulative incidence of revision surgery (41.6%; 95% CI, 31.8%-51%) than fixed-hinge prostheses did (64%; 95% CI, 50.5%-74.5% ) at 5 years (Gray's test: p = 0.01). According to the multivariate Fine and Gray model, the year of surgery did not have any effect on the risk of revision surgery (1994 to 2003: hazard ratio 0.70; 95% CI, 0.46-1.07); 2004 to 2016: HR 0.83; 95% CI, 0.52-1.34; p = 0.26). The multivariate analysis, adjusted for disease, sex, age, cementation, and year of surgery, revealed a difference in the risk of revision surgery between patients with oncologic disease and those with non-oncologic disease (HR 0.44 for oncologic versus non-oncologic; 95% CI, 0.22-0.87; p = 0.02) and a reduction in the risk of overall revision with cemented fixation in patients with oncologic disease (HR 0.53; 95% CI, 0.29-0.98; p = 0.03).
CONCLUSION: This study indicates that even with newer implants, there was a high incidence of revision surgery after distal femoral replacement. According to our analysis, patients with oncologic diagnoses have a lower likelihood of revision when the stem is cemented whereas the type of fixation did not impact patients with non-oncologic diagnoses. Because of differences in patient demographics (age, etiology of disease, and use of chemotherapy) and outcomes of fixation, oncologic and non-oncologic patients should be analyzed separately in survival studies about distal femoral replacement. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Year:  2020        PMID: 31895069      PMCID: PMC7170673          DOI: 10.1097/CORR.0000000000001106

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.755


  35 in total

1.  Survivorship and clinical outcome of modular endoprosthetic reconstruction for neoplastic disease of the lower limb.

Authors:  E R Ahlmann; L R Menendez; C Kermani; H Gotha
Journal:  J Bone Joint Surg Br       Date:  2006-06

2.  Survival of current production tumor endoprostheses: complications, functional results, and a comparative statistical analysis.

Authors:  E Pala; E R Henderson; T Calabrò; A Angelini; C N Abati; G Trovarelli; P Ruggieri
Journal:  J Surg Oncol       Date:  2013-09-04       Impact factor: 3.454

3.  What sports activity levels are achieved in patients with modular tumor endoprostheses of osteosarcoma about the knee?

Authors:  Nikolaus W Lang; Gerhard M Hobusch; Philipp T Funovics; Reinhard Windhager; Jochen G Hofstaetter
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

Review 4.  Bone effects of cancer therapies: pros and cons.

Authors:  Rebecca Silbermann; G David Roodman
Journal:  Curr Opin Support Palliat Care       Date:  2011-09       Impact factor: 2.302

5.  Tumor endoprosthesis revision rates increase with peri-operative chemotherapy but are reduced with the use of cemented implant fixation.

Authors:  Luke R Pugh; Paul W Clarkson; Amy E Phillips; David J Biau; Bassam A Masri
Journal:  J Arthroplasty       Date:  2014-01-21       Impact factor: 4.757

6.  Levels of silver ions in body fluids and clinical results in silver-coated megaprostheses after tumour, trauma or failed arthroplasty.

Authors:  Guido Scoccianti; Filippo Frenos; Giovanni Beltrami; Domenico Andrea Campanacci; Rodolfo Capanna
Journal:  Injury       Date:  2016-08-11       Impact factor: 2.586

7.  Experience with cemented large segment endoprostheses for tumors.

Authors:  Sanjeev Sharma; Robert E Turcotte; Marc H Isler; Cindy Wong
Journal:  Clin Orthop Relat Res       Date:  2007-06       Impact factor: 4.176

8.  Distal femoral replacement with the MML system: a single center experience with an average follow-up of 86 months.

Authors:  Andreas Toepfer; Norbert Harrasser; Paul-Ruben Schwarz; Florian Pohlig; Ulrich Lenze; Heinrich M L Mühlhofer; Ludger Gerdesmeyer; Ruediger von Eisenhart-Rothe; Christian Suren
Journal:  BMC Musculoskelet Disord       Date:  2017-05-22       Impact factor: 2.362

9.  Bone mineral loss induced by anticancer treatment for gynecological malignancies in premenopausal women.

Authors:  Keina Nishio; Akiko Tanabe; Risa Maruoka; Kiyoko Nakamura; Masaaki Takai; Tatsuharu Sekijima; Satoshi Tunetoh; Yoshito Terai; Masahide Ohmichi
Journal:  Endocr Connect       Date:  2012-11-19       Impact factor: 3.335

10.  Distal femoral reconstruction following failed total knee arthroplasty is accompanied with risk for complication and reduced joint function.

Authors:  Klemens Vertesich; Stephan E Puchner; Kevin Staats; Markus Schreiner; Christian Hipfl; Bernd Kubista; Johannes Holinka; Reinhard Windhager
Journal:  BMC Musculoskelet Disord       Date:  2019-01-31       Impact factor: 2.362

View more
  5 in total

1.  Long-term outcomes and improved risk of revision following tumor endoprosthetic replacement of the distal femur: Single institutional results.

Authors:  Charles A Gusho; Joshua A Greenspoon; Bishir Clayton; Jonathan Bauer; Matthew W Colman; Steven Gitelis; Alan T Blank
Journal:  J Orthop       Date:  2021-05-21

2.  CORR Insights®: Does a Competing Risk Analysis Show Differences in the Cumulative Incidence of Revision Surgery Between Patients with Oncologic and Nononcologic Conditions After Distal Femur Replacement?

Authors:  Carlos A Higuera-Rueda
Journal:  Clin Orthop Relat Res       Date:  2020-05       Impact factor: 4.755

3.  Distal femoral replacement - Cemented or cementless? Current concepts and review of the literature.

Authors:  Alexander B Christ; Francis J Hornicek; Nicola Fabbri
Journal:  J Clin Orthop Trauma       Date:  2021-05-08

4.  Long-term competing risks for overall and cause-specific failure of rotating-hinge distal femoral arthroplasty for tumour reconstruction.

Authors:  Koichi Ogura; Tomohiro Fujiwara; Carol D Morris; Patrick J Boland; John H Healey
Journal:  Bone Joint J       Date:  2021-08       Impact factor: 5.385

5.  Revision TKA with a distal femoral replacement is at high risk of reinfection after two-stage exchange for periprosthetic knee joint infection.

Authors:  Jan Schwarze; Burkhard Moellenbeck; Christoph Theil; Kristian Nikolaus Schneider; Georg Gosheger; Tom Schmidt-Braekling; Thomas Ackmann; Ralf Dieckmann; Adrien Frommer; Sebastian Klingebiel
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-02-10       Impact factor: 4.342

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.